Related Experiment Video

Updated: May 29, 2026

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish
08:09

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish

Published on: June 7, 2018

Pharmacogenetics of genes across the doxorubicin pathway

David Jamieson1, Alan V Boddy

  • 1Newcastle University, Northern Institute for Cancer Research, Newcastle upon Tyne, NE2 4HH, UK.

Expert Opinion on Drug Metabolism & Toxicology
|September 17, 2011
PubMed
Abstract

Insights

Genetic variations in doxorubicin metabolism and transport genes are being studied for their clinical impact. Current evidence suggests limited utility for genetic testing in doxorubicin therapy due to inconsistent findings.

Area of Science:

  • Pharmacogenomics
  • Oncology
  • Drug Metabolism

Background:

  • Doxorubicin is a key chemotherapy agent for various cancers.
  • Significant inter-individual variability exists in doxorubicin's pharmacokinetics, efficacy, and toxicity.
  • Genetic polymorphisms in doxorubicin-related genes are hypothesized to explain this variability.

Purpose of the Study:

  • To review the current evidence on genetic polymorphisms influencing doxorubicin pharmacology.
  • To evaluate the potential clinical significance of these genetic variants.

Main Methods:

  • Review of studies investigating genetic variants in doxorubicin metabolism and transport genes.
  • Analysis of associations between genetic polymorphisms (e.g., in ABCB1, CRB1, CRB3) and doxorubicin pharmacokinetics, efficacy, and toxicity.

Main Results:

  • Evidence suggests genetic variants affect proteins involved in doxorubicin transport, metabolism, and action.
  • Specific single nucleotide polymorphisms (SNPs) in genes like ABCB1 and carbonyl reductases show associations with doxorubicin outcomes.
  • Reported associations between genetic variants and doxorubicin pharmacology are not consistently observed across studies.

Conclusions:

  • While genetic variants offer insights into doxorubicin pharmacology, findings are often inconsistent.
  • Current data indicates that genotyping for doxorubicin-related genetic variants may have limited clinical utility.
  • Further research is needed to clarify the role and clinical applicability of these genetic associations.

More Related Videos

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform06:21

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform

Published on: May 10, 2024

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo05:14

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

Published on: May 16, 2020

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
Pharmacogenetics and Pharmacogenomics: Overview01:29

Pharmacogenetics and Pharmacogenomics: Overview

Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...